Zydus Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ZYDUS
ZYDUS has four hundred and eight approved drugs.
There is one US patent protecting ZYDUS drugs. There are twenty-eight tentative approvals on ZYDUS drugs.
There are four patent family members on ZYDUS drugs in four countries and one thousand one hundred and nineteen supplementary protection certificates in nineteen countries.
Summary for Zydus
| International Patents: | 4 |
| US Patents: | 1 |
| Tradenames: | 326 |
| Ingredients: | 316 |
| NDAs: | 408 |
| Patent Litigation for Zydus: | See patent lawsuits for Zydus |
Drugs and US Patents for Zydus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Pharms | METOPROLOL TARTRATE | metoprolol tartrate | TABLET;ORAL | 212402-001 | Apr 19, 2023 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Zydus Pharms | PREGABALIN | pregabalin | CAPSULE;ORAL | 206752-002 | Dec 9, 2022 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Zydus Pharms | BUSPIRONE HYDROCHLORIDE | buspirone hydrochloride | TABLET;ORAL | 078888-003 | Feb 7, 2014 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zydus Pharms | POTASSIUM CHLORIDE | potassium chloride | TABLET, EXTENDED RELEASE;ORAL | 210395-002 | Sep 17, 2020 | AB1 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ZYDUS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
International Patents for Zydus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| India | 651MU2014 | ⤷ Start Trial |
| South Africa | 201606075 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2015128877 | ⤷ Start Trial |
| Philippines | 12016501686 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Zydus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1470124 | LUC00009 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: PALBOCICLIB, EVENTUELLEMENT SOUS LA FORME D'UN SEL , D'UN ESTER, D'UN AMIDE OU D'UN PROMEDICAMENT PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/16/1147 20161111 |
| 0740668 | 03C0017 | France | ⤷ Start Trial | PRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112 |
| 1315485 | 2015/028 | Ireland | ⤷ Start Trial | PRODUCT NAME: LUBIPROSTONE AND PHARMACEUTICALLY ACCEPTABLE SALTS FOR LUBIPROSTONE.; NAT REGISTRATION NO/DATE: PA148/002/001 20150213; FIRST REGISTRATION NO/DATE: PL21341/0003-0001 20120910 |
| 3209302 | C202330028 | Spain | ⤷ Start Trial | PRODUCT NAME: COMBINACION DE FOSLEVODOPA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA Y FOSCARBIDOPA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISM.; NATIONAL AUTHORISATION NUMBER: 88677-SE/H/0415/003/DC; DATE OF AUTHORISATION: 20230220; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 141371; DATE OF FIRST AUTHORISATION IN EEA: 20220825 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
